PL2943226T3 - Kompozycje terapeutyczne i sposoby obejmujące transfekcję mrna - Google Patents

Kompozycje terapeutyczne i sposoby obejmujące transfekcję mrna

Info

Publication number
PL2943226T3
PL2943226T3 PL14738078T PL14738078T PL2943226T3 PL 2943226 T3 PL2943226 T3 PL 2943226T3 PL 14738078 T PL14738078 T PL 14738078T PL 14738078 T PL14738078 T PL 14738078T PL 2943226 T3 PL2943226 T3 PL 2943226T3
Authority
PL
Poland
Prior art keywords
therapeutic compositions
methods involving
mrna transfection
involving mrna
transfection
Prior art date
Application number
PL14738078T
Other languages
English (en)
Polish (pl)
Inventor
Mark C. HERZBERG
Karen Farnie ROSS
Brent S. Sorenson
Original Assignee
Mark C. HERZBERG
Karen Farnie ROSS
Brent S. Sorenson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mark C. HERZBERG, Karen Farnie ROSS, Brent S. Sorenson filed Critical Mark C. HERZBERG
Publication of PL2943226T3 publication Critical patent/PL2943226T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL14738078T 2013-01-11 2014-01-10 Kompozycje terapeutyczne i sposoby obejmujące transfekcję mrna PL2943226T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361751504P 2013-01-11 2013-01-11
PCT/US2014/011041 WO2014110366A1 (en) 2013-01-11 2014-01-10 Therapeutic compositions and methods involving mrna transfection
EP14738078.6A EP2943226B1 (en) 2013-01-11 2014-01-10 Therapeutic compositions and methods involving mrna transfection

Publications (1)

Publication Number Publication Date
PL2943226T3 true PL2943226T3 (pl) 2019-09-30

Family

ID=51167392

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14738078T PL2943226T3 (pl) 2013-01-11 2014-01-10 Kompozycje terapeutyczne i sposoby obejmujące transfekcję mrna

Country Status (13)

Country Link
US (3) US20150344537A1 (cg-RX-API-DMAC10.html)
EP (2) EP2943226B1 (cg-RX-API-DMAC10.html)
JP (4) JP2016511230A (cg-RX-API-DMAC10.html)
KR (2) KR102056511B1 (cg-RX-API-DMAC10.html)
CN (1) CN105473163A (cg-RX-API-DMAC10.html)
AU (1) AU2014205298B2 (cg-RX-API-DMAC10.html)
CA (2) CA2901409C (cg-RX-API-DMAC10.html)
ES (1) ES2738315T3 (cg-RX-API-DMAC10.html)
IL (2) IL239898B (cg-RX-API-DMAC10.html)
NZ (1) NZ710495A (cg-RX-API-DMAC10.html)
PL (1) PL2943226T3 (cg-RX-API-DMAC10.html)
SG (2) SG10201603946PA (cg-RX-API-DMAC10.html)
WO (1) WO2014110366A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2943226B1 (en) * 2013-01-11 2019-03-13 Herzberg, Mark C. Therapeutic compositions and methods involving mrna transfection
US11253570B2 (en) 2016-11-07 2022-02-22 Medizinische Hochschule Hannover (Mhh) S100A8/S100A9-induced immunotolerance in newborn subjects
CN107841508A (zh) * 2017-11-29 2018-03-27 重庆市中医院 含抑铁素重组减毒沙门杆菌及构建方法、表达或递送载体
EP3553525A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Diagnostics of mild or advanced periodontitis
EP3553523A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Diagnostics of mild or advanced periodontitis
JP6891157B2 (ja) * 2018-11-15 2021-06-18 正生 池本 機能性ペプチド、それを用いた大腸炎用医薬およびデリバリー剤
CN114561381A (zh) * 2022-03-14 2022-05-31 桂林医学院 免疫mRNA及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2797402B1 (fr) * 1999-07-15 2004-03-12 Biomerieux Stelhys Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
AU7725500A (en) * 1999-09-30 2001-04-30 National Jewish Medical And Research Center Method for inhibition of pathogenic microorganisms
US7754676B2 (en) * 2000-09-15 2010-07-13 The United States Of America As Represented By The Department Of Health And Human Services Defensin-antigen fusion proteins
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
DE10121254A1 (de) * 2001-04-30 2002-11-07 Switch Biotech Ag MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind
WO2004089292A2 (en) * 2003-04-04 2004-10-21 The Regents Of The University Of California Immunomodulatory agents for treatment of inflammatory diseases
DE10324997A1 (de) * 2003-06-03 2004-12-23 Switch Biotech Ag Mrp8/Mrp14 Inhibitoren und ihre Verwendung zur Prävention und/oder Behandlung von hypertrophen Narben und Keloiden
WO2005084180A2 (en) 2003-12-19 2005-09-15 University Of Cincinnati Polyamides and polyamide complexes for delivery of oligonucleotide decoys
WO2006085987A2 (en) * 2004-07-09 2006-08-17 University Of Iowa Research Foundation Rna interference in respiratory epitheial cells
WO2006078717A2 (en) * 2005-01-19 2006-07-27 Beth Israel Deaconess Medical Center Lipocalin 2 for the treatment, prevention, and management of cancer metastasis, angiogenesis, and fibrosis
KR100681763B1 (ko) * 2005-02-28 2007-02-15 재단법인 목암생명공학연구소 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법
US8501478B2 (en) 2006-06-15 2013-08-06 University Of Cincinnati Trehalose click polymers for delivery of biologically active molecules
EP2167653A2 (en) * 2007-06-11 2010-03-31 University Of Vermont And State Agricultural College Treatments involving glutaredoxins and similar agents
US8916163B1 (en) * 2007-12-21 2014-12-23 Vanderbilt University Method for treating microbial infections
DE102010040153A1 (de) * 2010-09-02 2012-03-08 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Stoffkombination zur Behandlung von entzündlichen oder infektiösen Erkrankungen
CA2831613A1 (en) * 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US10174081B2 (en) * 2011-04-21 2019-01-08 George Mason Research Foundation, Inc. Antimicrobial peptides and uses therefore
EP2943226B1 (en) * 2013-01-11 2019-03-13 Herzberg, Mark C. Therapeutic compositions and methods involving mrna transfection

Also Published As

Publication number Publication date
IL239898A0 (en) 2015-08-31
WO2014110366A1 (en) 2014-07-17
EP2943226B1 (en) 2019-03-13
SG11201505431XA (en) 2015-08-28
EP3501551C0 (en) 2023-06-07
US11912744B2 (en) 2024-02-27
EP2943226A4 (en) 2016-11-23
IL262252B (en) 2020-06-30
JP6473729B2 (ja) 2019-02-20
CN105473163A (zh) 2016-04-06
US20240166701A1 (en) 2024-05-23
US12448421B2 (en) 2025-10-21
US20200231640A1 (en) 2020-07-23
KR102056511B1 (ko) 2019-12-16
EP3501551B1 (en) 2023-06-07
JP2017052781A (ja) 2017-03-16
EP3501551A1 (en) 2019-06-26
KR20180026811A (ko) 2018-03-13
CA3152721C (en) 2025-11-18
ES2738315T3 (es) 2020-01-21
KR20160031999A (ko) 2016-03-23
JP2016511230A (ja) 2016-04-14
AU2014205298B2 (en) 2018-11-01
IL239898B (en) 2018-10-31
JP2019031521A (ja) 2019-02-28
EP2943226A1 (en) 2015-11-18
CA3152721A1 (en) 2014-07-17
KR102119985B1 (ko) 2020-06-05
CA2901409C (en) 2022-06-07
AU2014205298A1 (en) 2015-08-13
JP6956059B2 (ja) 2021-10-27
NZ710495A (en) 2019-10-25
US20150344537A1 (en) 2015-12-03
CA2901409A1 (en) 2014-07-17
IL262252A (en) 2018-11-29
JP2021019644A (ja) 2021-02-18
SG10201603946PA (en) 2016-07-28

Similar Documents

Publication Publication Date Title
IL273205A (en) Preparations and methods
IL286759A (en) Therapeutic methods and preparations
GB2533892B (en) Compositions and methods
ZA201504902B (en) Bcl-2bcl-xl inhibitors and therapeutic methods using the same
ZA201506487B (en) Therapeutic compounds and compositions
EP3043824A4 (en) Modified therapeutic agents and compositions thereof
GB201320723D0 (en) Composition and methods of treatment
GB201308072D0 (en) Compositions and methods
SG10201913930UA (en) Therapeutic nuclease compositions and methods
EP2884984A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD
SG11201508167PA (en) Therapeutic compositions and uses thereof
GB201311361D0 (en) Compounds and their therapeutic use
IL262252B (en) Therapeutic compositions and methods involving mrna transfection
GB2515865B (en) Use of galactooligosaccharides in therapy
GB201305813D0 (en) Compositions and methods
EP2941273A4 (en) Compositions and methods for polynucleotide transfection
IL245529A0 (en) Rapidly disintegrating formulations and methods of use
GB201308736D0 (en) Compounds and their therapeutic use
IL244537A0 (en) New administration preparations and methods of their use
HUE050547T2 (hu) Oligoszaccharid konjugátumok és alkalmazási eljárások
GB2514124B (en) Turf Treatment
GB201319255D0 (en) Therapeutic compositions and methods
HK1227895A1 (en) Therapeutic methods and compositions
GB201322617D0 (en) Methods and compositions
GB201312393D0 (en) Compositions and Methods